Cardiovascular health in the menopausal woman: impact of the timing of hormone replacement therapy

References

• Rossouw JE, Anderson GL, Prentice RL, . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer MJ, Manson JE, . Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453–61
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer MJ, Colditz GA, . Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336: 1769–75
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933–41
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Colditz GA, Willett WC, . Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study. N Engl J Med 1991;325:756–62
   PubMed Web of Science ®Google Scholar
• Grady D, Rubin SM, Petitti DB, . Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–37
   PubMed Web of Science ®Google Scholar
• Grady D, Herrington D, Bittner V, . Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49–57
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, . Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280: 605–13
   PubMed Web of Science ®Google Scholar
• Vickers MR, Maclennan AH, Lawton B, . Main morbidities recorded in the Women’s International Study of long Duration Oestrogen after Menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007;335:239
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, . Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523–34
   PubMed Web of Science ®Google Scholar
• Cushman M, Kuller LH, Prentice R, . Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573–80
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Hendrix SL, Limacher M, . Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA 2003; 289:2673–84
   PubMed Web of Science ®Google Scholar
• Prentice RL, Langer RD, Stefanick ML, . Combined analysis of Women’s Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol 2006;163:589–99
   PubMed Web of Science ®Google Scholar
• Curb JD, Prentice RL, Bray PF, . Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166:772–80
   PubMed Web of Science ®Google Scholar
• Hendrix SL, Wassertheil-Smoller S, Johnson KC, . Effects of conjugated equine estrogen on stroke in the Women’s Health Initiative. Circulation 2006;113:2425–34
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, . Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21:363–6
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15: 35–44
   PubMed Web of Science ®Google Scholar
• Hernán MA, Alonso A, Logan R, . Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology 2008;19:766–79
   PubMed Web of Science ®Google Scholar
• Karas RH. Current controversies regarding the cardiovascular effects of hormone therapy. Clin Obstet Gynecol 2004;47:489–99
   PubMed Web of Science ®Google Scholar
• Willett WC, Manson JE, Stampfer MJ, . Weight, weight change, and coronary heart disease in women. Risk within the ‘normal’ weight range. JAMA 1995;273:461–5
   PubMed Web of Science ®Google Scholar
• Shetty KD, Vogt WB, Bhattacharya J. Hormone replacement therapy and cardiovascular health in the United States. Med Care 2009;47:600–6
   PubMed Web of Science ®Google Scholar
• Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996;143:971–8
   PubMed Web of Science ®Google Scholar
• Karas RH, Clarkson TB. Considerations in interpreting the cardiovascular effects of hormone replacement therapy observed in the WHI: timing is everything. Menopausal Med 2003;10:8–12
   Google Scholar
• Clarkson TB, Appt SE. Controversies about HRT – lessons from monkey models. Maturitas 2005;51:64–74
   PubMed Web of Science ®Google Scholar
• Herrington DM, Reboussin DM, Brosnihan KB, . Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522–9
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Azen SP, . Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535–45
   PubMed Web of Science ®Google Scholar
• Waters DD, Alderman EL, Hsia J, . Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432–40
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Lobo RA, . Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939–53
   PubMed Web of Science ®Google Scholar
• Manson JE, Allison MA, Rossouw JE, . Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356: 2591–602
   PubMed Web of Science ®Google Scholar
• Allison MA, Manson JE, Langer RD, . Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women’s Health Initiative coronary artery calcium study. Menopause 2008;15:639–47
   PubMed Web of Science ®Google Scholar
• Goodman N, Goldzieher J, Ayala C. Critique of the report from the Writing Group of the WHI. Menopausal Med 2003;10:1–4
   PubMedGoogle Scholar
• Vitale C, Mercuro G, Cerquetani E, . Time since menopause influences the acute and chronic effect of estrogens on endothelial function. Arterioscler Thromb Vasc Biol 2008;28:348–52
   PubMed Web of Science ®Google Scholar
• Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994;89:1501–10
   PubMed Web of Science ®Google Scholar
• Post WS, Goldschmidt-Clermont PJ, Wilhide CC, . Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999;43:985–91
   PubMed Web of Science ®Google Scholar
• Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645–50
   PubMed Web of Science ®Google Scholar
• Tannen RL, Weiner MG, Xie D, Barnhart K. Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. Hum Reprod 2007;22:1769–77
   PubMed Web of Science ®Google Scholar
• Sorensen KE, Dorup I, Hermann AP, Mosekilde L. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 1998;97:1234–8
   PubMed Web of Science ®Google Scholar
• Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:217–21
   PubMed Web of Science ®Google Scholar
• Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336:1227–31
   PubMed Web of Science ®Google Scholar
• Vrablik M, Fait T, Kovar J, Poledne R, Ceska R. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. Metabolism 2008;57:1088–92
   PubMed Web of Science ®Google Scholar
• Alessandri N, Piccioni MG, Isabelli V, . Morphological and functional changes of cardiovascular system in postmenopausal women. Eur Rev Med Pharmacol Sci 2007;11:107–17
   PubMed Web of Science ®Google Scholar
• Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993;98:83–90
   PubMed Web of Science ®Google Scholar
• Sowers MR, Randolph J Jr, Jannausch M, Lasley B, Jackson E, McConnell D. Levels of sex steroid and cardiovascular disease measures in premenopausal and hormone-treated women at midlife: implications for the ‘timing hypothesis’. Arch Intern Med 2008;168:2146–53
   PubMed Web of Science ®Google Scholar
• Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583–7
   PubMed Web of Science ®Google Scholar
• Schindler TH, Campisi R, Dorsey D, . Effect of hormone replacement therapy on vasomotor function of the coronary microcirculation in post-menopausal women with medically treated cardiovascular risk factors. Eur Heart J 2009;30:978–86
   PubMed Web of Science ®Google Scholar
• Huang AJ, Sawaya GF, Vittinghoff E, Lin F, Grady D. Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. Menopause 2009;16:639–43
   PubMed Web of Science ®Google Scholar
• Szmuilowicz ED, Manson JE, Rossouw JE, . Vasomotor symptoms and cardiovascular events in postmenopausal women. Menopause 2011;18:603–10
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease. Obstet Gynecol 2008;112:1189–92
   PubMedGoogle Scholar
• North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15: 584–602
   PubMed Web of Science ®Google Scholar
• Miller VM, Black DM, Brinton EA, . Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2009;2:228–39
   PubMed Web of Science ®Google Scholar
• ELITE: Early Versus Late Intervention Trial With Estradiol. ClinicalTrials.gov Identifier: NCT00114517. http://www.clinicaltrials.gov/ct2/show/NCT00114517 [serial online]; accessed May 30, 2008
   Google Scholar